ArticleThe Journal of experimental medicine2013
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.
Article in The Journal of experimental medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 80 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 3 syntheses or guidelines pooled it, 156 citations in OpenAlex.
- Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review).International journal of molecular medicine · 2023Pooled it
- Cellular localization of nucleolin determines the prognosis in cancers: a meta-analysis.Journal of molecular medicine (Berlin, Germany) · 2022Pooled it
- Pooled it
- Curcumol Inhibits the Invasion and Migration of Breast Cancer via miR-206/NCL/ERα36.Phytotherapy research : PTR · 2026Article
- Retraction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.The Journal of experimental medicine · 2026Article
- Review
- Synthesis and Evaluation of AS1411-Lenalidomide-Targeted Degradation Chimera in Antitumor Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Dissecting the tRNA Fragment tRF3E-Nucleolin Interaction: Implications in Breast Cancer.Biomolecules · 2025Article
- The functions and modifications of tRNA-derived small RNAs in cancer biology.Cancer metastasis reviews · 2025Review
- Deciphering ovarian cancer heterogeneity through spatial transcriptomics, single-cell profiling, and copy number variations.PloS one · 2025Article
- Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells.BMC medicine · 2024Article
- Beyond biomarkers: Exploring the diverse potential of a novel phosphoprotein in lung cancer management.Journal of cellular and molecular medicine · 2024Review
- Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release.Journal of translational medicine · 2024Article
- Aptamer-functionalized nanomaterials (AFNs) for therapeutic management of hepatocellular carcinoma.Journal of nanobiotechnology · 2024Review
- LncRNA SNHG26 promotes gastric cancer progression and metastasis by inducing c-Myc protein translation and an energy metabolism positive feedback loop.Cell death & disease · 2024Article
- Emerging roles of tRNA-derived small RNAs in cancer biology.Experimental & molecular medicine · 2023Review
- An insight into fluorescence and magnetic resonance bioimaging using a multifunctional polyethyleneimine-passivated gadocarbon dots nanoconstruct assembled with AS1411.Mikrochimica acta · 2023Article
- An ERK1/2-driven RNA-binding switch in nucleolin drives ribosome biogenesis and pancreatic tumorigenesis downstream of RAS oncogene.The EMBO journal · 2023Article
- Article
- DriverMP enables improved identification of cancer driver genes.GigaScience · 2022Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
- Retraction · 2026-06-30Falsification/Fabrication of Data · Investigation by Company/Institution · Investigation by Journal/Publisher · Unreliable Results and/or Conclusions · Upgrade/Update of Prior Notice(s) · · see also: https://pubpeer.com/publications/7CE1513713E1DEC84FC992920225A1
- Expression of concern · 2022-10-03Concerns/Issues about Image · Investigation by Company/Institution · Investigation by Journal/Publisher · Updated to Retraction · Upgrade/Update of Prior Notice(s) ·
- Correction · 2017-01-19Error in Image · Updated to Expression of Concern ·
- Erratum issued
- Expression of concern
- Retracted
Authors and funding
22 authors at 5 institutions in 2 countries.
Funding
Abstract
Numerous studies have described the altered expression and the causal role of microRNAs (miRNAs) in human cancer. However, to date, efforts to modulate miRNA levels for therapeutic purposes have been challenging to implement. Here we find that nucleolin (NCL), a major nucleolar protein, posttranscriptionally regulates the expression of a specific subset of miRNAs, including miR-21, miR-221, miR-222, and miR-103, that are causally involved in breast cancer initiation, progression, and drug resistance. We also show that NCL is commonly overexpressed in human breast tumors and that its expression correlates with that of NCL-dependent miRNAs. Finally, inhibition of NCL using guanosine-rich aptamers reduces the levels of NCL-dependent miRNAs and their target genes, thus reducing breast cancer cell aggressiveness both in vitro and in vivo. These findings illuminate a path to novel therapeutic approaches based on NCL-targeting aptamers for the modulation of miRNA expression in the treatment of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.